A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally to adults with advanced or metastatic solid tumors with certain KRAS mutations.

Trial Details

NCT ID
NCT07458347
Phase
PHASE1
Sponsor
Kestrel Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • KST-6051
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Sarasota, Florida, United States|27.33643,-82.53065
  • Tampa, Florida, United States|27.94752,-82.45843
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362

Key Eligibility Criteria

  • Age ≥ 18 years.
  • Willing and able to give written informed consent.
  • Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor.
  • Documentation of KRAS mutation prior to the first dose of trial drug(s).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →